Pirche Partners with Natera to Enhance Transplant Medicine
Pirche AG has announced a strategic collaboration with Natera, Inc. to advance transplant medicine and immunosuppression. The partnership aims to improve patient care by integrating pre-transplant immunological risk assessment with post-transplant molecular monitoring using Natera’s Prospera™ test.
BERLIN–(BUSINESS WIRE)– #EpitopeLevelTransplantMatching–Pirche AG, a leader in digital molecular risk assessment, today announced a new collaboration to advance the field of transplant medicine and immunosuppression. In a strategic collaboration with Natera, Inc., a global leader in cell-free DNA testing and precision medicine, the companies aim to improve patient care by connecting pre-transplant immunological risk assessment with advanced post-transplant molecular monitoring using Natera’s Prospera™ test. Under the terms o